ClinicalTrials.gg
CompletedNCT01617655Updated Oct 4, 2016Results posted

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

A Phase 3 interventional study of Alirocumab and Placebo (for alirocumab) in Hypercholesterolaemia, sponsored by Sanofi. Completed at 35 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-04.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
22nd of 43
107 · median 107
Started
2012
with 11 others
Phase 3
20 of 43
none open now
Registered
12th of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 22nd largest by enrollment, is one of 12 that started in 2012, is one of 20 in phase 3, and was the 12th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).

Primary Objective of the study:

To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 24 weeks of treatment in comparison with placebo.

Secondary Objectives:

  • To evaluate the effect of alirocumab in comparison with placebo on LDL-C at other time points
  • To evaluate the effects of alirocumab on other lipid parameters
  • To evaluate the safety and tolerability of alirocumab
Read the detailed description

The maximum study duration was planned to be 89 weeks per participant including participants who successfully completed the 78-week treatment period had the possibility to join an open-label extension study (LTS13463, NCT01954394) at the end of the treatment period.

03

Conditions studied

  • Hypercholesterolaemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with heterozygous familial hypercholesterolemia who were not adequately controlled with their lipid-modifying therapy.

Exclusion criteria

Exclusion criteria:

  • Age \< 18 years
  • LDL-C \< 160 mg/dL (\< 4.14 mmol/L) at the screening visit (Week-3).
  • Fasting serum triglycerides > 400 mg/dL (> 4.52 mmol/L) during the screening period.
  • Known history of homozygous familial hypercholesterolemia.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
107 participants (actual)

Study arms

  • Placebo comparator
    Placebo Q2W

    Placebo for alirocumab subcutaneous (SC) injection every two weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.

    Drug: Placebo (for alirocumab) · Drug: Lipid Modifying Therapy (LMT)

  • Experimental
    Alirocumab 150 mg Q2W

    Alirocumab 150 mg SC injection Q2W on top of stable LMT for 78 weeks.

    Drug: Alirocumab · Drug: Lipid Modifying Therapy (LMT)

Interventions

  • Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).

    Also known as: SAR236553, REGN727, Praluent

  • DrugPlacebo (for alirocumab)

    Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).

  • DrugLipid Modifying Therapy (LMT)

    Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 - ITT Analysis

    Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 52

Secondary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection (on-treatment analysis).

    Time frame: From Baseline to Week 52

  2. Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  3. Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection.

    Time frame: From Baseline to Week 52

  4. Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  5. Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 52

  6. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  7. Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 52

  8. Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  9. Percent Change From Baseline in Apo B at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  10. Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  11. Percent Change From Baseline in Total-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  12. Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis

    Adjusted LS means and standard errors at Week 52 from MMRM model including all available post-baseline data from week 4 to week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  13. Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis

    Very high CV risk participants: Heterozygous Familial Hypercholesterolemia (heFH) participants with coronary heart disease (CHD) or CHD risk equivalents. High CV risk participants: heFH participants without CHD or CHD risk equivalents. CHD risk equivalent: peripheral arterial disease, ischemic stroke, moderate chronic kidney disease (estimated glomerular filtration rate, 30 to \<60 ml/minute/1.73 m\^2 of body-surface area), or diabetes mellitus plus 2 or more additional risk factors (hypertension; ankle-brachial index of ≤0.90; microalbuminuria, macroalbuminuria, or a urinary dipstick result of \>2+ protein; preproliferative or proliferative retinopathy or laser treatment for retinopathy; or a family history of premature CHD). Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model.

    Time frame: Up to Week 52

  14. Percentage of Very High CV Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - On-Treatment Analysis

    Adjusted percentages at Week 24 from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection.

    Time frame: Up to Week 52

  15. Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  16. Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  17. Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  18. Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  19. Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  20. Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  21. Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  22. Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  23. Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

    Adjusted percentages at Week 24 from multiple imputation approach including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: Up to Week 52

  24. Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis

    Adjusted percentages at Week 24 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection.

    Time frame: Up to Week 52

Other outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 52 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection.

    Time frame: From Baseline to Week 52

  2. Percent Change From Baseline in Calculated LDL-C at Week 78 - ITT Analysis

    Adjusted LS means and standard errors at Week 78 from MMRM model including all available post-baseline data from Week 4 to Week 78 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 78

  3. Percent Change From Baseline in Calculated LDL-C at Week 78 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 78 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 78 i.e. up to 21 days after last injection.

    Time frame: From Baseline to Week 78

07

Results

Posted Nov 6, 2015
Limitations and caveats
Manual reclassification was done by the Sponsor for the "other reasons" of non-completion of study as specified in the electronic case report form (eCRF).

Participant flow

The study was conducted at 33 centers in 5 countries. A total of 206 participants were screened between June 2012 and May 2013, 99 of whom were screen failures. Screen failures were mainly due to exclusion criteria met.

Participant flow — Overall Study
MilestonePlacebo Q2WAlirocumab 150 mg Q2W
Started3572
Treated3572
Completed2643
Not completed929
Withdrew: Adverse event23
Withdrew: Poor compliance to protocol14
Withdrew: Participants moved04
Withdrew: Consent withdrawn by participant11
Withdrew: Last visit outside protocol visit window110
Withdrew: Site closure35
Withdrew: Other than specified above12

Outcome measures

PrimaryPercent Change From Baseline in Calculated LDL-C at Week 24 - ITT Analysis

Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 24 - ITT Analysis-6.6 ± 4.9-45.7 ± 3.5
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -39.1 · 95% CI -51.1 to -27.1Alirocumab vs Placebo
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection (on-treatment analysis).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis-6.6 ± 5-45.5 ± 3.5
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -38.9 · 95% CI -51 to -26.9Alirocumab vs Placebo
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis-6.6 ± 4.6-46.9 ± 3.2
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -40.3 · 95% CI -51.4 to -29.3Alirocumab vs Placebo
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis-6.6 ± 4.6-46.9 ± 3.2
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -40.3 · 95% CI -51.4 to -29.2Alirocumab vs Placebo
SecondaryPercent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis-8.7 ± 3.8-39 ± 2.7
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -30.3 · 95% CI -39.7 to -20.9Alirocumab vs Placebo
SecondaryPercent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis-8.7 ± 3.9-38.9 ± 2.8
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -30.2 · 95% CI -39.7 to -20.7Alirocumab vs Placebo
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis-6.2 ± 4.3-41.9 ± 3.1
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -35.8 · 95% CI -46.3 to -25.3Alirocumab vs Placebo
SecondaryPercent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis-6.1 ± 4.3-41.7 ± 3.1
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -35.5 · 95% CI -46.2 to -24.9Alirocumab vs Placebo
SecondaryPercent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis-4.8 ± 3.6-33.2 ± 2.6
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -28.4 · 95% CI -37.3 to -19.6Alirocumab vs Placebo
SecondaryPercent Change From Baseline in Apo B at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis-9 ± 3.7-39.2 ± 2.6
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -30.2 · 95% CI -39.2 to -21.1Alirocumab vs Placebo
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis-6.9 ± 4.3-41.4 ± 3
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -34.5 · 95% CI -44.8 to -24.1Alirocumab vs Placebo
SecondaryPercent Change From Baseline in Total-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis-5.2 ± 3.5-33 ± 2.4
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -27.8 · 95% CI -36.2 to -19.4Alirocumab vs Placebo
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis

Adjusted LS means and standard errors at Week 52 from MMRM model including all available post-baseline data from week 4 to week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis-3 ± 5.9-42.1 ± 4.2
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -39.1 · 95% CI -53.6 to -24.6Alirocumab vs Placebo
SecondaryPercentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis

Very high CV risk participants: Heterozygous Familial Hypercholesterolemia (heFH) participants with coronary heart disease (CHD) or CHD risk equivalents. High CV risk participants: heFH participants without CHD or CHD risk equivalents. CHD risk equivalent: peripheral arterial disease, ischemic stroke, moderate chronic kidney disease (estimated glomerular filtration rate, 30 to \<60 ml/minute/1.73 m\^2 of body-surface area), or diabetes mellitus plus 2 or more additional risk factors (hypertension; ankle-brachial index of ≤0.90; microalbuminuria, macroalbuminuria, or a urinary dipstick result of \>2+ protein; preproliferative or proliferative retinopathy or laser treatment for retinopathy; or a family history of premature CHD). Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model.

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis
percentage of participantsPlacebo Q2WAlirocumab 150 mg Q2W
Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis5.741.0
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Regression, Logistic · p = 0.0016 (Threshold for significance ≤ 0.05.) · Odds ratio (or): 11.7 · 95% CI 2.5 to 53.5Alirocumab vs Placebo
SecondaryPercentage of Very High CV Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - On-Treatment Analysis

Adjusted percentages at Week 24 from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection.

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Very High CV Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - On-Treatment Analysis
percentage of participantsPlacebo Q2WAlirocumab 150 mg Q2W
Percentage of Very High CV Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - On-Treatment Analysis5.741.4
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Regression, Logistic · p = 0.0014 (Threshold for significance ≤ 0.05.) · Odds ratio (or): 11.9 · 95% CI 2.6 to 54.9Alirocumab vs Placebo
SecondaryPercent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis-8.7 ± 5-23.5 ± 3.7
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Regression, Robust · p = 0.0164 (Threshold for significance ≤ 0.05.) · Adjusted mean difference: -14.8 · 95% CI -26.9 to -2.7Alirocumab vs Placebo
SecondaryPercent Change From Baseline in HDL-C at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis3.9 ± 2.77.5 ± 1.9
Statistical analysis
  • Placebo Q2W vs Alirocumab 150 mg Q2W · Mixed Models Analysis · p = 0.2745 (Threshold for significance ≤ 0.05.) · Ls mean difference: 3.7 · 95% CI -2.9 to 10.2Alirocumab vs Placebo
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis-1.9 ± 4.8-10.5 ± 3.3
SecondaryPercent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis2 ± 2.15.6 ± 1.5
SecondaryPercent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis-1.5 ± 5.1-23.2 ± 3.6
SecondaryPercent Change From Baseline in HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis8.0 ± 3.47.9 ± 2.4
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis-4.4 ± 5.1-9.4 ± 3.7
SecondaryPercent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis1.1 ± 2.24.6 ± 1.5
SecondaryPercentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

Adjusted percentages at Week 24 from multiple imputation approach including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
percentage of participantsPlacebo Q2WAlirocumab 150 mg Q2W
Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis2.932.4
SecondaryPercentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis

Adjusted percentages at Week 24 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection.

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
percentage of participantsPlacebo Q2WAlirocumab 150 mg Q2W
Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis2.932.6
Other pre-specifiedPercent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 52 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis-2.9 ± 6.1-42.0 ± 4.4
Other pre-specifiedPercent Change From Baseline in Calculated LDL-C at Week 78 - ITT Analysis

Adjusted LS means and standard errors at Week 78 from MMRM model including all available post-baseline data from Week 4 to Week 78 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 78
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 78 - ITT Analysis
percent changePlacebo Q2WAlirocumab 150 Q2W
Percent Change From Baseline in Calculated LDL-C at Week 78 - ITT Analysis1.2 ± 6.4-37.9 ± 4.5
Other pre-specifiedPercent Change From Baseline in Calculated LDL-C at Week 78 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 78 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 78 i.e. up to 21 days after last injection.

Time frame:
From Baseline to Week 78
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 78 - On-Treatment Analysis
percent changePlacebo Q2WAlirocumab 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 78 - On-Treatment Analysis-0.2 ± 6.2-40.9 ± 4.5

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit in the study regardless of seriousness or relationship to study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Q2W—4/35 (11.4%)20/35 (57.1%)
Alirocumab 150 Q2W—10/72 (13.9%)39/72 (54.2%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPlacebo Q2WAlirocumab 150 Q2W
Anaphylactic reactionImmune system disorders1/350/72
Angina pectorisCardiac disorders1/351/72
Biliary colicHepatobiliary disorders1/350/72
Rheumatoid arthritisMusculoskeletal and connective tissue disorders1/350/72
Renal colicRenal and urinary disorders1/350/72
Myocardial infarctionCardiac disorders0/352/72
BronchitisInfections and infestations0/351/72
DiverticulitisInfections and infestations0/351/72
Carpal tunnel syndromeNervous system disorders0/351/72
Acute coronary syndromeCardiac disorders0/351/72
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlacebo Q2WAlirocumab 150 Q2W
NasopharyngitisInfections and infestations4/3510/72
InfluenzaInfections and infestations1/359/72
DiarrhoeaGastrointestinal disorders3/354/72
MyalgiaMusculoskeletal and connective tissue disorders3/354/72
Injection site reactionGeneral disorders2/356/72
Urinary tract infectionInfections and infestations0/355/72
DizzinessNervous system disorders0/355/72
HeadacheNervous system disorders0/355/72
FatigueGeneral disorders0/355/72
BronchitisInfections and infestations2/354/72

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo Q2WAlirocumab 150 mg Q2WTotal
Mean52.1 ± 11.249.8 ± 14.250.6 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Q2WAlirocumab 150 mg Q2WTotal
Female133750
Male223557
Calculated LDL-C in mg/dL
Calculated LDL-C in mg/dL(mg/dL)Placebo Q2WAlirocumab 150 mg Q2WTotal
Mean201 ± 43.4196.3 ± 57.9197.8 ± 53.4
Calculated low density lipoprotein cholesterol (LDL-C) in mmol/L
Calculated low density lipoprotein cholesterol (LDL-C) in mmol/L(mmol/L)Placebo Q2WAlirocumab 150 mg Q2WTotal
Mean5.205 ± 1.1255.083 ± 1.4995.123 ± 1.382
08

Study locations

35 sites
  • Investigational Site Number 840742
    Bell Gardens, California 90201, United States
  • Investigational Site Number 840703
    Newport Beach, California 92660, United States
  • Investigational Site Number 840712
    Newport Beach, California 92663, United States
  • Investigational Site Number 840743
    Northridge, California 91324, United States
  • Investigational Site Number 840734
    Washington, District of Columbia 20037, United States
  • Investigational Site Number 840738
    Miami, Florida 33165, United States
  • Investigational Site Number 840710
    Ponte Vedra, Florida 32081, United States
  • Investigational Site Number 840701
    New York, New York 10032, United States
  • Investigational Site Number 840702
    Durham, North Carolina 27710, United States
  • Investigational Site Number 840714
    Cincinnati, Ohio 45219, United States
  • Investigational Site Number 840705
    Philadelphia, Pennsylvania 19104, United States
  • Investigational Site Number 840709
    Philadelphia, Pennsylvania 19104, United States
  • Investigational Site Number 840713
    Philadelphia, Pennsylvania 19104, United States
  • Investigational Site Number 840736
    Dallas, Texas 75216, United States
  • Investigational Site Number 124704
    Quebec, G1V 4M6, Canada
  • Investigational Site Number 124703
    Sherbrooke, J1H 5N4, Canada
  • Investigational Site Number 528713
    Amsterdam, 1091 AC, Netherlands
  • Investigational Site Number 528701
    Amsterdam, 1105 AZ, Netherlands
  • Investigational Site Number 528704
    Groningen, 9728 NT, Netherlands
  • Investigational Site Number 528716
    Leiden, 2333 ZA, Netherlands
  • Investigational Site Number 528709
    Utrecht, 3582 KE, Netherlands
  • Investigational Site Number 643706
    Arkhangelsk, 163000, Russian Federation
  • Investigational Site Number 643705
    Kazan, 420012, Russian Federation
  • Investigational Site Number 643703
    Moscow, 111539, Russian Federation
  • Investigational Site Number 643711
    Moscow, 121552, Russian Federation
  • Investigational Site Number 643708
    Moscow, 129301, Russian Federation
  • Investigational Site Number 643702
    Saint Petersburg, 197341, Russian Federation
  • Investigational Site Number 643710
    St-Petersburg, 193079, Russian Federation
  • Investigational Site Number 643709
    St-Petersburg, 194291, Russian Federation
  • Investigational Site Number 643707
    Yaroslavl, 150062, Russian Federation
  • Investigational Site Number 710701
    Bloemfontein, 9301, South Africa
  • Investigational Site Number 710704
    Bloemfontein, 9301, South Africa
  • Investigational Site Number 710706
    Cap Town, 7530, South Africa
  • Investigational Site Number 710702
    Parktown, 2193, South Africa
  • Investigational Site Number 710703
    Somerset West, 7130, South Africa
09

References and documents

Publications

  • Kastelein JJ, Robinson JG, Farnier M, Krempf M, Langslet G, Lorenzato C, Gipe DA, Baccara-Dinet MT. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther. 2014 Jun;28(3):281-9. doi: 10.1007/s10557-014-6523-z. PubMed 24842558 ↗
  • Ginsberg HN, Rader DJ, Raal FJ, Guyton JR, Baccara-Dinet MT, Lorenzato C, Pordy R, Stroes E. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Cardiovasc Drugs Ther. 2016 Oct;30(5):473-483. doi: 10.1007/s10557-016-6685-y. PubMed 27618825 ↗
  • Mahmood T, Minnier J, Ito MK, Li QH, Koren A, Kam IW, Fazio S, Shapiro MD. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. Eur J Prev Cardiol. 2021 Jul 23;28(8):816-822. doi: 10.1177/2047487320915803. Epub 2020 Apr 10. PubMed 34298554 ↗
  • Leiter LA, Tinahones FJ, Karalis DG, Bujas-Bobanovic M, Letierce A, Mandel J, Samuel R, Jones PH. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabet Med. 2018 Dec;35(12):1742-1751. doi: 10.1111/dme.13817. Epub 2018 Oct 9. PubMed 30183102 ↗
  • Defesche JC, Stefanutti C, Langslet G, Hopkins PN, Seiz W, Baccara-Dinet MT, Hamon SC, Banerjee P, Kastelein JJP. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. J Clin Lipidol. 2017 Nov-Dec;11(6):1338-1346.e7. doi: 10.1016/j.jacl.2017.08.016. Epub 2017 Sep 4. Erratum In: J Clin Lipidol. 2020 Sep - Oct;14(5):742. doi: 10.1016/j.jacl.2020.09.010. PubMed 28964736 ↗
  • Kastelein JJ, Hovingh GK, Langslet G, Baccara-Dinet MT, Gipe DA, Chaudhari U, Zhao J, Minini P, Farnier M. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017 Jan-Feb;11(1):195-203.e4. doi: 10.1016/j.jacl.2016.12.004. Epub 2016 Dec 28. PubMed 28391886 ↗
  • Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P, Eckel RH, Cannon CP. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016 Dec 13;134(24):1931-1943. doi: 10.1161/CIRCULATIONAHA.116.024604. Epub 2016 Oct 24. PubMed 27777279 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of May 2014 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 1 year 6 months after primary completion. A results delay was requested in Feb 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2012
First posted
Jun 12, 2012
Start
Jun 2012
Primary completionActual
May 2014
CompletionActual
Jan 2015
Results delay requested
Feb 9, 2015
Results first posted
Nov 6, 2015
Last update
Oct 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01617655
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 12, 2012
Start date
Jun 2012
Primary completion
May 2014
Completion
Jan 2015
Results posted
Nov 6, 2015
Last update
Oct 4, 2016

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion